Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — Technical Presentation (December 2020)
13 slides from Telix Pharmaceuticals's technical presentation, Dec 2, 2020
Slide 1: CUP D: First-in-Human Translation of TLX592
CUP D First-in-Human Translation of TLX592 (Targeted Alpha Therapy) Telix Pharmaceuticals Limited: Investor Briefing 2nd December 2020
Slide 2: Disclaimer
Disclaimer The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (“Telix”) in any jurisdiction, including the United States. No representation or warranty, express or implie
Slide 3: What is TLX592?
What is TLX592? • TLX592 is a promising “next generation” asset for PSMA- targeted therapy – combines the best attributes of monoclonal antibodies (selectivity) and small molecules (rapid clearance) • Antibody engineered for optimized kinetics / dosimetry for use with 225Ac (actinium) for Targeted A
Slide 4: Building on TLX591: anti-PSMA molecularly targeted radiation (MTR)
Building on TLX591 : anti-PSMA molecularly targeted radiation (MTR) • TLX591 (177Lu-DOTA-rosopatamab) has a compelling body of data, going into Ph III development • The knowledge base of TLX591 elegantly paves the way for “next generation” products (TLX592) • The clinical development objectives of T
Slide 5: What is TAT with 225Ac (actinium) and what is it intended for?
What is TAT with 225Ac (actinium) and what is it intended for? 225Ac is an alpha-emitting radionuclide (α-emitter) Antibody (mAb) TAT = Targeted • Half-life of ~10 days (long) Linker Alpha Therapy • Very high energy irradiation resulting from four α-particle (helium nucleus) decays, and >1,000x grea
Slide 6: TLX592 clears rapidly from the blood
TLX592 clears rapidly from the blood • TLX591 and TLX592 were dosed Antibody Pharmacokinetics in a comparatively in a validated humanised Humanised FcRn Mouse Model mouse model to simulate clinical (Jackson Laboratories) pharmacokinetics 100 T L X 5 9 1 (H u J 9 5 1 ) Ø TLX591 = 133.4 ± 6.8 hours ha
Slide 7: A picture is worth 1,000 words: excellent tumour targeting
A picture is worth 1,000 words : excellent tumour targeting TLX59 1 Imaging study comparing TLX591 and TLX592 • Blood pool, liver signal, spleen signal comparable (24hr) but then clearance is far faster with TLX592 TLX59 • Estimated serum half-life of 133 hours for TLX591 2 versus 12 hours for TLX59
Slide 8: Taking TLX592 into patients with a theranostic approach
Taking TLX592 into patients with a “theranostic” approach • The use of imaging is a powerful way to confirm targeting and kinetics of a new drug candidate • Imaging therapeutic drugs that contain 225Ac is not easy because α-emission is not detectable with conventional methods like Positron Emission
Slide 9: Study design: First-in-human study of TLX592
study design : First-in-human study of TLX592 CUPID = 64Cu PSMA Imaging and (Bio)Distribution • An open-label first-in-human (FIH) study of 64Cu-TLX592 in men with metastatic prostate cancer using Positron Emission Tomography (PET) • Rapid: expected to be completed in ~6 months • Single Site: Conduc
Slide 10: Dosing schedule
dosing schedule • Initial escalation in nine (9) early-stage biochemical recurrence (BCR) patients (n=3 per dose level): Ø Prostate cancer patients with low-burden metastatic disease at ≤ 5 3 X 3 dose sites as detected using PSMA PET/CT scanning (TLX591-CDx) escalation (6 Ø Three dose levels, 2mg, 1
Slide 11: How does TLX592 fit into Telix's commercial strategy?
How does TLX592 fit into Telix’s commercial strategy? PSMA Imaging (TLX591-CDx / TLX599-CDx) TLX592 TLX591 TLX592 PSMA-617 Telix Pharmaceuticals Limited (ASX: TLX) 11
Slide 12: Summary: Telix's "one-two punch" for prostate cancer
Summary : Telix’s “one-two punch” for prostate cancer TLX591 (177Lu-rosopatamab) TLX592 (225Ac-TLX592) Traditional humanised antibody immunoconjugate Engineered antibody immunoconjugate (RADMab®) designed well-validated for beta radiation for delivering targeted alpha radiation • Beta emitter (177Lu
Slide 13: telixpharma.com
TELIX PHARMACEUTICALS Precision Oncology. See it. Treat it. telixpharma.com
Telix Pharmaceuticals — Technical Presentation (December 2020) on 6ix